Dr. Harry Zhabilov holds a Doctor of Science , Ph.D , and M.D. degrees from Sofia University in Bulgaria.
He has been employed by Viral since 1995.
A native Bulgarian , Dr. ...
www.sec.gov [cached]
A native Bulgarian , Dr. Zhabilov now resides in the United States , and he has had extensive research experience in the immunotherapy of cancer and HIV/AIDS infections.Between 1971 and 1992 , Dr. Zhabilov was head of the Autoimmune Disease Research Laboratory at the Medical Academy of Sofia , Bulgaria.It was through Dr. Zhabilov's early work with autoimmune modulation in the treatment of various cancers that the concept of the Thymus Nuclear Protein ( TNP ) product was born.There was an agreement made with Therapeutic Genetics , Inc. to acquire all rights to all uses of TNP , including all patents , for $5 , 000 , 000.Viral Genetics , Inc. gave a promissory note for the amount , which includes interest at 5% per year , and provides for a royalty payment of 5% of gross sales for the life of the patents.There have been process and use patents issued for TNP as follows :.Australia
...
Dr. Harry ZhabilovCEO , Director
62
...
Dr. Harry Zhabilov , Director.Dr. Zhabilov holds a Doctor of Science , Ph.D , and M.D. degrees from Sophia University in Bulgaria.He has been employed by Viral Genetics , Inc. since 1995.Dr. Zhabilov has no direct or indirect ownership in 5 STARLIVING ONLINE INC , all ownership interests have been assigned to his children.
Recently Immunotech Laboratories (IMMB) ...
www.italianbiotech.com [cached]
Recently Immunotech Laboratories (IMMB) President Harry Zhabilov and Director Bo Linton welcomed UndiscoveredCompanies.com into their facilities to... [Read more...]
Zhabilov - Dedicated scientists ...
www.peoplepond.com [cached]
Zhabilov - Dedicated scientists and chemists research ways to fight immune diseases every day. Zhabilov Tweet &description=" class="pin-it-button" count-layout="horizontal">Pin It
About Harry Zhabilov:
With a Bachelor of Science, a Master's degree in Chemistry and Chemical Engineering, and decades of lab research and human subject testing alongside his father, Harry Zhabilov is well-qualified to act as President, Vice Chairman of the Board, and Chief Science Officer at Immunotech Laboratories, Inc., in Glendale, California. There, Harry Zhabilov commits himself to finding treatments and possible cures for a variety of immune deficiencies and infectious diseases. Years of hard work have led Harry Zhabilov to discover an important treatment for HIV/AIDS called IPF (irreversible pepsin fraction).
Cost-effective and more powerful than previous therapies, this drug proved a major breakthrough in the world of science, and Harry Zhabilov received a patent for it in January of 2009. IPF works for a wide range of applications and does not cause the common side effects of other anti-retroviral drugs, such as neurological, hematological, and gastrointestinal complications. Along with his colleagues, Harry Zhabilov authored a paper on IPS titled "Irreversible Pepsin Fraction (IPF) displays significant antiretroviral activity via specific novel cytokine stimulation in vitro investigation of activity on human lymphocytes. The paper showed significant results in fighting autoimmune diseases, particularly HIV/AIDS, with IPF.
As a proud member of the American Institute of Chemical Engineers (AIChE), Harry Zhabilov contributes to the organization formed for professionals in the field of chemical engineering as one of 40,000 members from more than 90 different countries. Through the AIChE, Harry Zhabilov holds access to important chemical engineering developments and networks with colleagues to share their collective knowledge. Harry Zhabilov also holds membership in the American Chemical Society, an outfit that represents professional scientists and chemists of all levels involved in a number of fields. Harry Zhabilov's father, Dr. Zhabilov Sr., served at the Bulgarian Academy of Sciences as one of the institution's leading research scientists.
Harry Zhabilov's important accomplishments result from working alongside his father in the lab for decades, and his father named him co-inventor of his work. Together they researched the thymus nuclear protein (TNP) and performed studies on both human subjects and conducted experimental testing. Devoted to studying the human immune system and exploring alternate approaches for the treatment of immune diseases, Harry Zhabilov and his father focused on HIV/AIDS.
Profiles in the Biotechnology Category
www.peoplepond.com [cached]
With a Bachelor of Science, a Master's degree in Chemistry and Chemical Engineering, and decades of lab research and human subject testing alongside his father, Harry Zhabilov is well-qualified to act as President, Vice Chairman of the Board, and Chief Science Officer at Immunotech Laboratories, Inc., in Glendale, California. There, Harry Zhabilov commits himself to finding treatments and possible cures for a variety of immune deficiencies and infectious diseases. Years of hard work have led Harry Zhabilov to discover an important treatment for HIV/AIDS called IPF (irreversible pepsin fraction). Cost-effective and more powerful than previous therapies, this drug proved a major breakthrough in the world of science, and Harry Zhabilov received a patent for it in January of 2009. IPF works for a wide range of applications and does not cause the common side effects of other anti-retroviral drugs, such as neurological, hematological, and gastrointestinal complications. Along with his colleagues, Harry Zhabilov authored a paper on IPS titled "Irreversible Pepsin Fraction (IPF) displays significant antiretroviral activity via specific novel cytokine stimulation in vitro investigation of activity on human lymphocytes. The paper showed significant results in fighting autoimmune diseases, particularly HIV/AIDS, with IPF. As a proud member of the American Institute of Chemical Engineers (AIChE), Harry Zhabilov contributes to the organization formed for professionals in the field of chemical engineering as one of 40,000 members from more than 90 different countries. Through the AIChE, Harry Zhabilov holds access to important chemical engineering developments and networks with colleagues to share their collective knowledge. Harry Zhabilov also holds membership in the American Chemical Society, an outfit that represents professional scientists and chemists of all levels involved in a number of fields. Harry Zhabilov's father, Dr. Zhabilov Sr., served at the Bulgarian Academy of Sciences as one of the institution's leading research scientists. Harry Zhabilov's important accomplishments result from working alongside his father in the lab for decades, and his father named him co-inventor of his work. Together they researched the thymus nuclear protein (TNP) and performed studies on both human subjects and conducted experimental testing. Devoted to studying the human immune system and exploring alternate approaches for the treatment of immune diseases, Harry Zhabilov and his father focused on HIV/AIDS.
News 
Market Data 
Discover 
AI
